The CTC positivity rates gained through this approach were clearly higher especially in NSCLC cases with brain metastases compared to other studies using, e.g., the EpCAM-dependent CELLSEARCH® system, with CTC positivity rates of only 12.5% [21]. This evidence concerns the gene EPCAM and non-small cell lung carcinoma.